Innate Pharma (NASDAQ:IPHA) Upgraded by BTIG Research to “Strong-Buy” Rating

BTIG Research upgraded shares of Innate Pharma (NASDAQ:IPHA) to a strong-buy rating in a research report released on Wednesday morning,Zacks.com reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Innate Pharma in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Innate Pharma Price Performance

Shares of IPHA opened at $1.50 on Wednesday. The company’s 50-day moving average is $1.71 and its 200-day moving average is $1.86. Innate Pharma has a fifty-two week low of $1.40 and a fifty-two week high of $2.63.

Institutional Investors Weigh In On Innate Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in shares of Innate Pharma during the fourth quarter worth $162,000. OLD Mission Capital LLC acquired a new position in shares of Innate Pharma in the fourth quarter valued at about $50,000. Finally, Millennium Management LLC bought a new position in Innate Pharma during the fourth quarter worth about $36,000. Institutional investors and hedge funds own 0.16% of the company’s stock.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.